李雨函,黄阳荣卓,周海玲,唐 娟

目的：探讨血清过氧化物酶6（Peroxiredoxin VI，PRDX6）与阿尔茨海默病（Alzheimer disease，AD）的关联以及与海马萎缩的相关性，为血清PRDX6成为AD无创辅助诊断标志物提供理论依据。方法：选取本院2024年10月至2025年9月确诊的50例AD患者为病例组，年龄、性别匹配的50例正常人为对照组，对患者完善认知评估量表和海马核磁检查。使用酶联免疫吸附法检测各组血清PRDX6的水平，并分析PRDX6水平与AD量表评分、海马萎缩分级的相关性，采用二元Logistic回归探讨PRDX6是否为AD的危险因素，绘制ROC曲线评估血清PRDX6在AD中的诊断价值。结果：AD组血清PRDX6的水平明显高于对照组（P<0.05）；血清PRDX6的水平在各海马萎缩组之间有显著差异（P<0.05），并且随着海马萎缩程度的加重呈现上升趋势；AD组中PRDX6的水平与简易精神状态检查量表（r=-0.904）和蒙特利尔认知评估量表（r=-0.765）呈负相关关系，与海马萎缩分级呈正相关（r=0.446，P<0.05）；二元Logistic回归发现，血清PRDX6是AD的危险因素，OR值为10.752，95%置信区间为（1.385，83.464）；血清PRDX6的ROC曲线下面积为0.67，灵敏度为50%，特异度为83.30%。结论：AD患者血清PRDX6水平显著升高，并且与认知功能呈负相关，与海马萎缩分级呈正相关；血清PRDX6诊断AD的特异性较好，对筛查AD患者有一定的价值。

阿尔茨海默病；PRDX6；神经心理学测验；海马；认知

[1] Nie Y,Chu C,Qin Q,et al.Lipid metabolism and oxidative stress in patients with Alzheimer's disease and amnestic mild cognitive impairment[J].Brain Pathology,2024,34(1):e13202. [2] Hansson O.Biomarkers for neurodegenerative diseases[J].Nature medicine,2021,27(6):954-963. [3] Guzman-Martinez L,Maccioni R B,Farías G A,et al.Biomarkers for Alzheimer's disease[J].Current Alzheimer Research,2019,16(6):518-528. [4] Paczynski M M,Day G S.Alzheimer disease biomarkers in clinical practice:a blood-based diagnostic revolution[J].Journal of Primary Care&Community Health,2022,13:21501319221141178. [5] Xue M,Huang X,Zhu T,et al.Unveiling the significance of peroxiredoxin 6 in central nervous system disorders[J].Antioxidants,2024,13(4):449. [6] Wu X,Zhang X L,Wang Y,et al.Peroxiredoxin 6 protects against oxidative stress and apoptosis in a rat model of lithium chloride- pilocarpine-induced epilepsy[J].Journal of biological regulators and homeostatic agents,2022,36(4):1017-1026. [7] Ge M,Zhang X,Xu C,et al.Peroxiredoxins in central nervous system:implications for chronic pain and anaesthetic-induced neurotoxicity management[J].Redox Biology,2025,87:103898. [8] Huang F,Liu Y,Wang Y,et al.Co-aggregation ofα-synuclein with amyloid-βstabilizesβ-sheet-rich oligomers and enhances the formation ofβ-barrels[J].Physical Chemistry Chemical Physics,2023,25(46):31604-31614. [9] Li Y,Yu H,Chen C,et al.Proteomic profile of mouse brain aging contributions to mitochondrial dysfunction,DNA oxidative damage,loss of neurotrophic factor,and synaptic and ribosomal proteins[J].Oxidative medicine and cellular longevity,2020,2020(1):5408452. [10] Akl E,Dyrba M,GörßD,et al.MRI for diagnosing dementia-update 2025[C]//RöFo-Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.Georg Thieme Verlag KG,2025. [11] 曹曦.TOM70表达异常参与阿尔茨海默病发病及相关机制的研究[D].济南:山东大学,2023. [12] 田金洲,时晶,张学凯,等.2011年美国阿尔茨海默病最新诊断标准解读[J].中国医学前沿杂志(电子版),2011,3(04):91-100. [13] Saha R,Assouline B,Mason G,et al.Impact of differences in acute respiratory distress syndrome randomised controlled trial inclusion and exclusion criteria:systematic review and meta-analysis[J].British Journal of Anaesthesia,2021,127(1):85-101. [14] Palmqvist S,Janelidze S,Quiroz Y T,et al.Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders[J].Jama,2020,324(8):772-781. [15] Astillero‐Lopez V,Gonzalez‐Rodriguez M,Villar‐Conde S,et al.Neurodegeneration and astrogliosis in the entorhinal cortex in Alzheimer's disease:stereological layer‐specific assessment and proteomic analysis[J].Alzheimer's&Dementia,2022,18(12):2468-2480. [16] Jia W,Dong C,Li B.Anti-oxidant and pro-oxidant effects of peroxiredoxin 6:a potential target in respiratory diseases[J].Cells,2023,12(1):181. [17] Szeliga M.Peroxiredoxins in neurodegenerative diseases[J].Antioxidants,2020,9(12):1203. [18] Power J H T,Asad S,Chataway T K,et al.Peroxiredoxin 6 in human brain:molecular forms,cellular distribution and association with Alzheimer's disease pathology[J].Acta neuropathologica,2008,115(6):611-622. [19] Young J S,Lee A T,Chang E F.A review of cortical and subcortical stimulation mapping for language[J].Neurosurgery,2021,89(3):331-342.

点击下载PDF